JUL 31·SEC EDGARLow
Wong Hing C purchased $60K of HCWB
Wong Hing C (Chief Executive Officer) purchased 23,210 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.
StockNASDAQ · US · USDHealthcare · Biotechnology
$HCWB
HCW Biologics Inc.
Price · $HCWBvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $HCWB in the last 7 days.
Insider · 30dAll trades →
- Buys
- $100K 3 txs
- Sells
- — 0 txs
Wong Hing C1× · $60K
10b5-1 plan0%
Top stories · $HCWBMore →
JUL 31·SEC EDGAR
Flowers Lee purchased $20K of HCWB
Flowers Lee (SVP of Business Development) purchased 7,736 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.
JUL 29·SEC EDGAR 8-K
HCW Biologics Inc. (HCWB): Entry into a Material Definitive Agreement
HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ex10-1.htm EX-10.1 Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is entered into and made effective as of July 29, 2026, by and among HCW Biologics Inc., a Delaware corporation (the “ Company ”), each purchase
HCWB sentiment & insider activity
Recent HCWB coverage spans insider activity, corporate actions and financial news.
In the last 30 days, HCWB insiders filed 3 SEC Form 4 transactions — 3 purchases ($100K) and no sales. The most active reporter was Wong Hing C, Chief Executive Officer, with 1 filing.
What's driving HCWB
A small open-market insider buy is a mild positive signal, but it is not large enough to materially change near-term fundamentals.
This is a routine Form 4 insider buy with modest size, offering limited incremental signal on near-term fundamentals.
The filing signals a capital raise structure (common stock plus pre-funded warrants and 5.5-year warrants), which can pressure near-term valuation via dilution risk.
Dilutive financing with warrant overhang, plus a near-term need for stockholder approval to issue common warrants.
Reverse split changes share count and can affect liquidity/technical levels, while the stated driver is Nasdaq listing compliance.
alphai scores every news story that mentions HCWB with an AI model for sentiment and relevance, and aggregates insider trades from HCW Biologics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $HCWB
Score
Wong Hing C purchased $60K of HCWB
Wong Hing C (Chief Executive Officer) purchased 23,210 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.
2 min readFlowers Lee purchased $20K of HCWB
Flowers Lee (SVP of Business Development) purchased 7,736 shares of HCW Biologics Inc. (HCWB) at $2.58 on 2026-07-29.
1 min readHCW Biologics Inc. (HCWB): Entry into a Material Definitive Agreement
HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ex10-1.htm EX-10.1 Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is entered into and made effective as of July 29, 2026, by and among HCW Biologics Inc., a Delaware corporation (the “ Company ”), each purchase
6 min readHCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
HCW Biologics Inc. (NASDAQ: HCWB) priced a $1.6 million private placement, issuing 618,682 units at $2.585 per unit. Each unit includes one common share (or a pre-funded warrant) and a common warrant, subject to stockholder approval. Net proceeds will fund clinical trials for HCW9302 and IND-enabling work for HCW11-018b and HCW11-040.
3 min read
HCW Biologics Sets 1-for-6 Reverse Stock Split For June 30; Shares Slide
HCW Biologics Inc. (HCWB) said its board approved a 1-for-6 reverse stock split effective before the open on June 30, 2026, after Nasdaq Hearings Panel requirements. The company expects shares to trade on a split-adjusted basis under the same ticker. Outstanding shares will fall from 9.58 million to about 1.60 million; no fractional shares will be issued. HCWB was $1.05, down 6.25%.
2 min readHCW Biologics Inc. (HCWB): Submission of Matters to a Vote of Security Holders
HCW Biologics Inc. (HCWB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001828673 0001828673 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min read
Insider Buying: HCW Biologics (NASDAQ:HCWB) CFO Purchases 14,235 Shares of Stock
HCW Biologics CFO Rebecca Byam bought 14,235 shares of NASDAQ:HCWB on May 22 at an average $1.41/share, for about $20,071, according to an SEC filing. The purchase raised her direct stake to 57,245 shares (~$80,715). The stock fell 26% recently to $1.94. The company reported $0.37 EPS and $6.54M revenue for the quarter.
4 min readWong Hing C purchased $160K of HCWB
Wong Hing C (Chief Executive Officer) purchased 113,879 shares of HCW Biologics Inc. (HCWB) at $1.40 ($0.16M total) on 2026-05-22.
1 min readGARRETT SCOTT T purchased $250K of HCWB (indirect holdings)
GARRETT SCOTT T purchased 177,936 indirectly-held shares of HCW Biologics Inc. (HCWB) at $1.40 ($0.25M total) on 2026-05-22.
1 min readByam Rebecca purchased $20K of HCWB
Byam Rebecca (Chief Financial Officer) purchased 14,235 shares of HCW Biologics Inc. (HCWB) at $1.40 on 2026-05-22.
1 min read